Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Transepicardial Atrial Injection of Saline
NCT05634213Phase 1Withdrawn
- Sponsor
- University of Ottawa Heart Institute
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoints: Recruitment uptake at 1 year, Treatment fidelity at 1 year and 1 more. Planned start Mar 2023; status: withdrawn.
Beyond the preview
Go deeper on NCT05634213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634213.